Literature DB >> 30914466

Clinical and Prognostic Characteristics of 53 Cases of Extracranial Malignant Rhabdoid Tumor in Children. A Single-Institute Experience from 2007 to 2017.

Haiyan Cheng1, Shen Yang1, Siyu Cai2, Xiaoli Ma3, Hong Qin1, Weiping Zhang4, Libing Fu5, Qi Zeng6, Mingjie Wen7,8, Xiaoxia Peng2, Huanmin Wang9.   

Abstract

BACKGROUND: The aim of this study is to add to the current knowledge regarding extracranial malignant rhabdoid tumor (MRT), a rare and highly aggressive tumor that occurs most commonly in infants and young children. PATIENTS AND METHODS: A retrospective medical record review was conducted on 53 patients with pathologically confirmed MRT in Beijing Children's Hospital between January 2007 and October 2017.
RESULTS: Fifty-three patients were diagnosed with MRT at a median age of 16 months, including 32 cases of malignant rhabdoid tumor of the kidney (MRTK) and 21 cases of extrarenal extracranial rhabdoid tumor (EERT). Fourteen (14/32, 43.75%) patients with MRTK and five (5/21, 23.81%) patients with EERT had metastases at diagnosis, and quite a few number of cases occurred tumor rupture (26.42%). Among the 53 patients, 40 (75.47%) patients died, 10 (18.87%) patients survived, and 3 patients (5.66%) were lost to follow-up. Among the 40 dead patients, 38 patients died from rapid progression of the disease or tumor recurrence, and 2 patients died of severe postoperative complications. Most of the recurrent or relapsed cases (94.11%) occurred within 8 months, with a median time of 76 days after diagnosis. The overall survival rates of 3 years and 5 years for the entire cohort were 23.71% and 18.44%, respectively. After survival analysis, it was clear that a younger age at diagnosis and distant stage patients had relatively poor outcomes. The effect of treatment was the most difficult to analyze because patients were not treated uniformly. Statistically significant differences in survival were noted among patients treated with standard chemotherapy, total resection, and radiotherapy.
CONCLUSION: Extracranial MRT is still a highly aggressive tumor in children. Younger patients and those suffering from metastatic disease were most likely to have a poor outcome because of rapid progression or recurrence of the tumor. IMPLICATIONS FOR PRACTICE: This is the largest single-institutional report that investigates the clinical characteristics and outcomes of extracranial malignant rhabdoid tumor (MRT) in China. Our study showed that gross hematuria and tumor rupture were typical characteristics of malignant rhabdoid tumor of the kidney. After survival analysis, it was found that the advanced stage of the tumor and an age ≤12 months at diagnosis were significantly associated with poorer survival. Although extracranial MRT is still a highly aggressive tumor in children, multimodal treatment approach, including chemotherapy, surgery, and radiotherapy, should be employed for this disease. © AlphaMed Press 2019.

Entities:  

Keywords:  Clinical characteristics; Extracranial malignant rhabdoid tumor; Prognosis; Treatment schedules

Mesh:

Year:  2019        PMID: 30914466      PMCID: PMC6656446          DOI: 10.1634/theoncologist.2018-0416

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  18 in total

Review 1.  Clinical presentation of rhabdoid tumors of the kidney.

Authors:  A M Amar; G Tomlinson; D M Green; N E Breslow; P A de Alarcon
Journal:  J Pediatr Hematol Oncol       Date:  2001-02       Impact factor: 1.289

2.  Rhabdoid tumor of the kidney in the National Wilms' Tumor Study: age at diagnosis as a prognostic factor.

Authors:  Gail E Tomlinson; Norman E Breslow; Jeffrey Dome; Katherine Adams Guthrie; Pat Norkool; Sierra Li; Patrick R M Thomas; Elizabeth Perlman; J Bruce Beckwith; Giulio J D'Angio; Daniel M Green
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

3.  Immunohistochemical analysis of hSNF5/INI1 distinguishes renal and extra-renal malignant rhabdoid tumors from other pediatric soft tissue tumors.

Authors:  Andrew C Hoot; Pierre Russo; Alexander R Judkins; Elizabeth J Perlman; Jaclyn A Biegel
Journal:  Am J Surg Pathol       Date:  2004-11       Impact factor: 6.394

4.  Extracranial malignant rhabdoid tumors in childhood: the Childrens Hospital Los Angeles experience.

Authors:  Catherine E Madigan; Saro H Armenian; Marcio H Malogolowkin; Leo Mascarenhas
Journal:  Cancer       Date:  2007-11-01       Impact factor: 6.860

5.  Rhabdoid tumour: a malignancy of early childhood with variable primary site, histology and clinical behaviour.

Authors:  Xiangru Wu; Vinod Dagar; Elizabeth Algar; Andrea Muscat; Pratiti Bandopadhayay; David Ashley; Chung Wo Chow
Journal:  Pathology       Date:  2008-12       Impact factor: 5.306

Review 6.  Rhabdoid tumor of the kidney with spontaneous rupture: case report and review of literature.

Authors:  Chi-Jen Chang; Ming-Lun Yeh; Cha-Chun Chen
Journal:  Pediatr Surg Int       Date:  2007-05-10       Impact factor: 1.827

7.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

Review 8.  Malignant rhabdoid tumor of the liver: case report and literature review.

Authors:  Takashi Yuri; Naoyuki Danbara; Nobuaki Shikata; Sachiko Fujimoto; Takahide Nakano; Noriko Sakaida; Yoshiko Uemura; Airo Tsubura
Journal:  Pathol Int       Date:  2004-08       Impact factor: 2.534

9.  Long-term survival after autologous peripheral blood stem cell transplantation in two patients with malignant rhabdoid tumor of the kidney.

Authors:  Yuhki Koga; Akinobu Matsuzaki; Aiko Suminoe; Miho Hatano; Yusuke Saito; Yoshiaki Kinoshita; Tatsuro Tajiri; Tomoaki Taguchi; Kenichi Kohashi; Yoshinao Oda; Masazumi Tsuneyoshi; Toshiro Hara
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

10.  Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors.

Authors:  Iyad Sultan; Ibrahim Qaddoumi; Carlos Rodríguez-Galindo; Anwar Al Nassan; Khalil Ghandour; Maysa Al-Hussaini
Journal:  Pediatr Blood Cancer       Date:  2010-01       Impact factor: 3.167

View more
  9 in total

1.  Immune-Related LncRNAs as Prognostic Factors for Pediatric Rhabdoid Tumor of the Kidney.

Authors:  Ye Hong; Yi Que; Yang Hu; Bo-Yun Shi; Jia Zhu; Juan Wang; Jun-Ting Huang; Fei-Fei Sun; Lian Zhang; Xin-Ke Zhou; Su-Ying Lu; Yi-Zhuo Zhang
Journal:  Dis Markers       Date:  2022-06-15       Impact factor: 3.464

2.  Infantile Extracranial Rhabdoid Tumor of the Scalp.

Authors:  Sura Al Rawabdeh; Deifallah Alsharari; Hayat Khasawneh; Ola M Al Waqfi; Qamar Yaser Malabeh; Hiathem Abu Alhaija; Raed Mohammad Aljubour; Hamzeh M Alkhawaldeh
Journal:  Case Rep Med       Date:  2021-05-11

3.  Identification of prognostic immune-related genes in rhabdoid tumor of kidney based on TARGET database analysis.

Authors:  Huimou Chen; Suying Lu; Jinqiu Guan; Xiaoqin Zhu; Feifei Sun; Junting Huang; Jia Zhu; Juan Wang; Zijun Zhen; Yi Que; Xiaofei Sun; Yizhuo Zhang
Journal:  Aging (Albany NY)       Date:  2021-02-11       Impact factor: 5.682

Review 4.  Current and Emerging Therapeutic Approaches for Extracranial Malignant Rhabdoid Tumors.

Authors:  Karolina Nemes; Pascal D Johann; Stefanie Tüchert; Patrick Melchior; Christian Vokuhl; Reiner Siebert; Rhoikos Furtwängler; Michael C Frühwald
Journal:  Cancer Manag Res       Date:  2022-02-09       Impact factor: 3.989

5.  Fetal-onset malignant rhabdoid tumor: a case report.

Authors:  Ryota Kobayashi; Wakako Sumiya; Toshiyuki Imanishi; Chika Kanno; Masayuki Kanno; Jun Unemoto; Ken Kawabata; Masami Kanno; Masaki Shimizu
Journal:  J Med Case Rep       Date:  2022-07-20

6.  Clinical and prognostic analysis of 42 children with malignant rhabdoid tumor of the kidney: a 7-year retrospective multi-center study.

Authors:  Chenghao Zhanghuang; Zhaoxia Zhang; Li Zeng; Bing Yan; Haoyu Tang; Jinkui Wang; Xing Liu; Guanghui Wei; Dawei He
Journal:  BMC Pediatr       Date:  2022-10-13       Impact factor: 2.567

7.  Dual targeting of EZH1 and EZH2 for the treatment of malignant rhabdoid tumors.

Authors:  Haruka Shinohara; Rie Sawado; Makoto Nakagawa; Ayuna Hattori; Kazutsune Yamagata; Kimiharu Tauchi; Jumpei Ito; Yasumichi Kuwahara; Tsukasa Okuda; Chitose Ogawa; Issay Kitabayashi
Journal:  Mol Ther Oncolytics       Date:  2022-09-19       Impact factor: 6.311

8.  An analysis of the diagnosis, clinical characteristics, treatment, and survival outcomes of 36 extracranial malignant rhabdoid tumor patients.

Authors:  Yuhua Shan; Jiaoyang Cai; Yali Han; Chenjie Xie; Honxiang Gao; Lei Zhang; Jingjing Li; Ruicheng Tian; Yu Liang; Jing Wang; Changcheng Chen; Bin Ji; Jingyan Tang; Min Xu; Song Gu
Journal:  Transl Pediatr       Date:  2021-06

Review 9.  A Systematic Review and Meta-Analysis of Malignant Rhabdoid and Small Cell Undifferentiated Liver Tumors: A Rational for a Uniform Classification.

Authors:  Juri Fuchs; Anastasia Murtha-Lemekhova; Markus Kessler; Fabian Ruping; Patrick Günther; Alexander Fichtner; Dominik Sturm; Katrin Hoffmann
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.